A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

An aerosol-generating device includes an electrical power supply, a cavity structure configured to receive an aerosol-generating article, and a plurality of semiconductor heaters within the cavity structure. Each of the plurality of semiconductor heaters includes a substrate layer and a heating layer on the substrate layer. The heating layer is a continuous layer. The aerosol-generating device includes a controller configured to control a supply of electrical power from the electrical power supply to each of the plurality of semiconductor heaters.

Proposed devices operate on positive pressure with as little as 5-6 ml of air and can efficiently empty (emitted doses >80%) and deliver the aerosol to infant lungs (lung delivery efficiency of ˜60% of the loaded dose). Significant features include internal flow structure of the air-jet DPI, automatic gas sources, infant-specific interfaces, small diameter nasopharyngeal tubes, sealed nasal prongs, 3D rod array preceding patient interface, nasal CPAP rapid aerosol delivery system, nasal CPAP streamlined interface, multidose storage and delivery unit, and pressure sensing near the infant airways (at the nasal cannula interface).

The present disclosure relates to an aerosol delivery device that includes a reservoir housing that defines a mouthpiece channel. The aerosol delivery device includes a sealing member configured to be received within the reservoir housing to define a reservoir chamber configured to retain an aerosol precursor composition therein. The aerosol delivery device also includes a substrate member that is configured to be received within the reservoir housing and to be directly engaged with a vaporizing assembly for forming an aerosol. The reservoir housing, sealing member, substrate member, and/or vaporizing assembly can be used for forming aerosols with precise and reproducible compositions.

The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Disclosed is a ratchet mechanism having ratchet ring and a chassis. The ratchet ring is rotatable about an axis relative to the chassis, with a general direction of rotation determined by teeth of the ratchet mechanism. The ratchet ring has a first set of teeth arranged regularly around the ratchet ring and protruding in a first axial direction from the ratchet ring and a second set of teeth arranged regularly around the ratchet ring and protruding in a second opposite axial direction from the ratchet ring. The chassis has a third set of teeth arranged regularly and protruding in the second axial direction and generally opposed to the first set of teeth, and a fourth set of teeth arranged regularly and protruding in the first axial direction and generally opposed to the second set of teeth.

A nozzle (10) for a container for the intranasal administration of a liquid formulation comprises a nozzle body (12) with an upper end (18) and a lower end (16), a channel (40) traversing the nozzle body (12) and ending with an orifice (17) in the upper end (18), and a nozzle cover (14) covering an area of the outer surface of the nozzle body (12) which is designed to be introduced into a user's nostril, wherein the nozzle body (12) is made out of a first material and the nozzle cover (14) is made out of a second material, said first material being a rigid plastic material, and said second material being an elastic plastic material, and wherein the nozzle cover (14) is not in contact with the orifice (17). A packaging for a liquid formulation for intranasal administration comprises a container and such nozzle (10). A product comprises such a packaging and a liquid formulation in said packaging.

The present disclosure provides a heating assembly and an atomization device. The atomization device includes an oil guiding member and a heating member. The oil guiding member has a through hole cutting through the oil guiding member. The through hole is configured to guide atomized gas generated on the oil guiding member out of the oil guiding member. The oil guiding member includes a connecting part. The connecting part is located in the through hole. The connecting part spans the through hole along a radial direction of the through hole. The heating member is embedded in one end of the oil guiding member. At least part of the heating member is located on the connecting part. The heating member is used for heating the oil guiding member, so that the liquid to be atomized is atomized on an end face of the oil guiding member close to the heating member.

The present invention provides an inhalation device with which it is possible to improve usability and promote users' safety and satisfaction with the inhalation device. An inhalation device according to the present invention is provided with a first member and a second member which is configured to be capable of being attached to and detached from the first member. This inhalation device includes: an active functional part which is provided to the first member; a passive functional part which is provided to the second member and which is capable of changing the state thereof according to the working of the active functional part; a sensor part which is provided to the first member and which detects a changed state of the passive functional part; and a control part which, on the basis of the detected state, determines whether the second member has been attached to the first member.

A dose ring for a dry powder inhaler (DPI) device includes an aluminum foil member covering particulate medication cavities and through holes. The device includes hinged flaps formed by a cut so that one radial side is uncut and forms a hinge. Each flap can cover both a cavity for particulate medication and a through hole located between that cavity and the circular inside edge of the dose ring.